Trial Outcomes & Findings for Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries (NCT NCT04198571)

NCT ID: NCT04198571

Last Updated: 2024-03-26

Results Overview

Clinical response in CAP was defined as participants demonstrating clinical stability (i.e., according to the Infectious Disease Society of America \[IDSA\] guidelines a temperature of less than or equal to (\<=) 37.8 degree Celsius, heart rate of \<=100 beats per minute, respiratory rate of \<=24 breaths per minute, systolic blood pressure of greater than or equal to (\>=) 90 millimeters of mercury (mmHg), oxygen saturation of \>=90%, and confusion/disorientation recorded as absent) and clinical improvement (i.e., improvement of at least 1 of 4 symptoms present at Baseline \[i.e., cough, dyspnea, pleuritic chest pain, sputum production\] with worsening of none). Clinical response in cSSTI participants was defined as \>=20% reduction from baseline infection area and cessation of spread measured by total infection area.

• Recruitment status: COMPLETED
• Target enrollment: 317 participants
• Primary outcome timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)
• Results posted on: 2024-03-26

Participant Flow

Participants hospitalized for Community Acquired Pneumonia (CAP) or Complicated Soft Skin Tissue Infections (cSSTI) and treated with four or more consecutive intravenous (IV) doses of Zinforo (ceftaroline fosamil) in a usual care setting on or before 31-May-2019, were included. Data was collected retrospectively from hospital records and evaluated over approximately 14 months of this study.

Participant milestones

Measure	Participants With CAP Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 milligram (mg) administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Overall Study STARTED	185	132
Overall Study COMPLETED	185	132
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.	Total n=317 Participants Total of all reporting groups
Age, Customized 18 to less than or equal to 65 years	90 Participants n=185 Participants	83 Participants n=132 Participants	173 Participants n=317 Participants
Age, Customized Greater than 65 years	95 Participants n=185 Participants	49 Participants n=132 Participants	144 Participants n=317 Participants
Sex: Female, Male Female	76 Participants n=185 Participants	55 Participants n=132 Participants	131 Participants n=317 Participants
Sex: Female, Male Male	109 Participants n=185 Participants	77 Participants n=132 Participants	186 Participants n=317 Participants
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical response in CAP was defined as participants demonstrating clinical stability (i.e., according to the Infectious Disease Society of America [IDSA] guidelines a temperature of less than or equal to (<=) 37.8 degree Celsius, heart rate of <=100 beats per minute, respiratory rate of <=24 breaths per minute, systolic blood pressure of greater than or equal to (>=) 90 millimeters of mercury (mmHg), oxygen saturation of >=90%, and confusion/disorientation recorded as absent) and clinical improvement (i.e., improvement of at least 1 of 4 symptoms present at Baseline [i.e., cough, dyspnea, pleuritic chest pain, sputum production] with worsening of none). Clinical response in cSSTI participants was defined as >=20% reduction from baseline infection area and cessation of spread measured by total infection area.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Clinical Response	151 Participants	118 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Clinical response in CAP was defined as participants demonstrating clinical stability (i.e., according to the IDSA guidelines a temperature of <=37.8 degree Celsius, heart rate of <=100 beats per minute, respiratory rate of <=24 breaths per minute, systolic blood pressure of >=90 mmHg, oxygen saturation of >=90%, and confusion/disorientation recorded as absent) and clinical improvement (i.e., improvement of at least 1 of 4 symptoms present at Baseline (i.e., cough, dyspnea, pleuritic chest pain, sputum production) with worsening of none). Clinical response in cSSTI participants was defined as >=20% reduction from baseline infection area and cessation of spread measured by total infection area.

Outcome measures

Measure	Participants With CAP n=151 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=118 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time to Clinical Response	4 Days Interval 0.0 to 18.0	4 Days Interval 0.0 to 26.0

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical cure for both CAP and cSSTI was defined as the resolution of clinical features or improvement status requiring no further antibiotic therapy. Participants who achieved clinical cure were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Achieved Clinical Cure	115 Participants	72 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Clinical cure for both CAP and cSSTI was defined as the resolution of clinical features or improvement status requiring no further antibiotic therapy. Time taken to achieve the clinical cure was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=115 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=72 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time to Clinical Cure	7 Days Interval 1.0 to 25.0	5 Days Interval 1.0 to 28.0

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical failure for both CAP and cSSTI was defined as any of the following: treatment modification due to adverse event (AE); drug-drug interaction; insufficient response (followed by switch); death due to index infection; death due to other cause; relapse or recurrence.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Clinical Failure	34 Participants	14 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, up to maximum of 35 days (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Clinical failure was defined as any of the following: treatment modification due to AE; drug-drug interaction; insufficient response (followed by switch); death due to index infection; death due to other cause; relapse or recurrence. Number of participants with CAP, according to the reasons for their clinical failure were reported in this outcome measure. Only those reasons which had at least 1 participant has been reported.

Outcome measures

Measure	Participants With CAP n=34 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants According to Reasons for Clinical Failure Insufficient response	21 Participants	—
CAP: Number of Participants According to Reasons for Clinical Failure Death due to index infection	7 Participants	—
CAP: Number of Participants According to Reasons for Clinical Failure Death due to other	2 Participants	—
CAP: Number of Participants According to Reasons for Clinical Failure Relapse or recurrence	2 Participants	—
CAP: Number of Participants According to Reasons for Clinical Failure Unknown	2 Participants	—

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, up to maximum of 60 days (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Clinical failure was defined as any of the following: treatment modification due to AE; drug-drug interaction; insufficient response (followed by switch); death due to index infection; death due to other cause; relapse or recurrence. Number of participants with cSSTI, according to the reasons for their clinical failure were reported in this outcome measure. Only those reasons which had at least 1 participant has been reported.

Outcome measures

Measure	Participants With CAP n=14 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Reasons for Clinical Failure Treatment modification due to AE	1 Participants	—
cSSTI: Number of Participants According to Reasons for Clinical Failure Insufficient response	10 Participants	—
cSSTI: Number of Participants According to Reasons for Clinical Failure Relapse or recurrence	3 Participants	—

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, up to maximum of 35 days (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

Clinical stability was defined according to the IDSA guidelines as temperature of <=37.8 degree Celsius, heart rate of <=100 beats per minute, respiratory rate of <=24 breaths per minute, systolic blood pressure of >=90 mmHg, oxygen saturation of >=90%, and confusion/disorientation recorded as absent. The time to achieve clinical stability was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP Only: Time to Clinical Stability	3 Days Interval 0.0 to 17.0	—

PRIMARY outcome

Timeframe: Baseline (before Day 1 of Zinforo treatment) till end of Zinforo treatment, up to maximum of 35 days [from the retrospective data evaluated in approximately 14 months of the study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

Clinical improvement was defined as improvement of at least 1 of 4 symptoms present at Baseline (i.e., cough, dyspnea, pleuritic chest pain, sputum production) with worsening of none. The time to clinical improvement was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP Only: Time to Clinical Improvement	3 Days Interval 0.0 to 18.0	—

PRIMARY outcome

Timeframe: Within 4 days after treatment with Zinforo (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical response in CAP was defined as participants demonstrating clinical stability (i.e., according to the IDSA guidelines a temperature of <=37.8 degree Celsius, heart rate of <=100 beats per minute, respiratory rate of <=24 breaths per minute, systolic blood pressure of >=90 mmHg, oxygen saturation of >=90%, and confusion/disorientation recorded as absent) and clinical improvement (i.e., improvement of at least 1 of 4 symptoms present at Baseline [i.e., cough, dyspnea, pleuritic chest pain, sputum production] with worsening of none). Participants with CAP who showed response within 4 days after treatment with Zinforo were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants With Early Response Within 4 Days	79 Participants	—

PRIMARY outcome

Timeframe: Within 3 days after treatment with Zinforo (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical response in cSSTI participants was defined as >=20% reduction from baseline infection area and cessation of spread measured by total infection area. Participants with cSSTI who showed response within 3 days after treatment with Zinforo were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants With Early Response Within 3 Days	20 Participants	—

PRIMARY outcome

Timeframe: Baseline (before Day 1 of treatment) till end of treatment, up to maximum of 60 days [from the retrospective data evaluated in approximately 14 months of the study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The response to treatment in cSSTI participants was measured as >=20% reduction from baseline in infection area.

Outcome measures

Measure	Participants With CAP n=118 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI Only: Time to Greater Than or Equal to (>=) 20% Reduction From Baseline in Infection Area	3 Days Interval 0.0 to 10.0	—

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, up to maximum of 60 days (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The response to treatment in cSSTI participants was measured as cessation of spread of infection measured by total infection area.

Outcome measures

Measure	Participants With CAP n=118 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI Only: Time to Cessation of Spread Measured by Total Infection Area	2 Days Interval 0.0 to 26.0	—

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, up to maximum of 60 days (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Time taken for the cessation of spread of infection as measured by length and width of the infected area was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=118 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI Only: Time to Cessation of Spread Measured by Infection Length and Width	2 Days Interval 0.0 to 7.0	—

PRIMARY outcome

Timeframe: At discharge from hospital: any day till 102 days for CAP; any day till 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Participants were categorized based on the discharge status in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Discharge Status Died in the hospital	18 Participants	6 Participants
Number of Participants According to Discharge Status Discharged to a nursing home or extended care facility	28 Participants	23 Participants
Number of Participants According to Discharge Status Discharged to independent living (with or without support)	138 Participants	101 Participants
Number of Participants According to Discharge Status Other	1 Participants	2 Participants

PRIMARY outcome

Timeframe: Within 30 days after discharge from hospital (discharge was any day till 102 days for CAP; any day till 162 days for cSSTI) [from the retrospective data evaluated in approximately 14 months of the study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who were re-hospitalized within 30 days of discharge were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Re-hospitalization Within 30 Days of Discharge	20 Participants	13 Participants

PRIMARY outcome

Timeframe: Within 30 days after discharge from hospital (discharge was any day till 102 days for CAP; any day till 162 days for cSSTI) [from the retrospective data evaluated in approximately 14 months of the study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to the vital status in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Vital Status Within 30 Days of Discharge Participant is still alive	126 Participants	98 Participants
Number of Participants According to Vital Status Within 30 Days of Discharge Participant is deceased	31 Participants	15 Participants
Number of Participants According to Vital Status Within 30 Days of Discharge Unknown	28 Participants	19 Participants

PRIMARY outcome

Timeframe: From 1 week before Zinforo treatment through 24 hours post discontinuation of Zinforo treatment during index hospitalization (102 days for CAP; 162 days for cSSTI) [from retrospective data evaluated in approximately 14 months of study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

MIC was defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism. Participants were categorized as Yes, No or Unknown against being assessed for MIC.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Minimum Inhibitory Concentration (MIC) Assessment Yes	23 Participants	28 Participants
Number of Participants According to Minimum Inhibitory Concentration (MIC) Assessment No	161 Participants	94 Participants
Number of Participants According to Minimum Inhibitory Concentration (MIC) Assessment Unknown	1 Participants	10 Participants

PRIMARY outcome

Timeframe: From Day 1 of Index hospitalization till MIC assessment, any day till 102 days for CAP; any day till 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Day of MIC assessment since the index hospitalization was reported in this outcome measure. Index hospitalization was first hospitalization on or before May 31, 2019 where Zinforo was administered for the treatment of CAP or cSSTI.

Outcome measures

Measure	Participants With CAP n=23 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=28 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Day of MIC Assessment Since Index Hospitalization	1 Days Interval 0.0 to 10.0	4 Days Interval -10.0 to 47.0

PRIMARY outcome

Timeframe: From 1 week before Zinforo treatment through 24 hours post discontinuation of Zinforo treatment during index hospitalization (102 days for CAP; 162 days for cSSTI) [from retrospective data evaluated in approximately 14 months of study]

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Pathogens for bacterial pneumonia were identified by blood, respiratory (e.g., sputum, bronchoalveolar lavage), or pleural effusion cultures and pathogens for cSSTI were identified blood or skin/soft tissue/bone/wound cultures. Number of participants with MIC of antibacterial drugs for pathogens isolated from samples were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=23 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=28 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to MIC of Antibacterial Drugs Assessed Based on Pathogens MIC of ceftaroline for all isolated pathogens	5 Participants	7 Participants
Number of Participants According to MIC of Antibacterial Drugs Assessed Based on Pathogens MIC of oxacillin, vancomycin, linezolid, and daptomycin for Staphylococcus aureus	12 Participants	20 Participants
Number of Participants According to MIC of Antibacterial Drugs Assessed Based on Pathogens MIC of ceftriaxone for Methicillin-Susceptible Staphylococcus aureus (MSSA)	3 Participants	6 Participants
Number of Participants According to MIC of Antibacterial Drugs Assessed Based on Pathogens MIC of penicillin and ceftriaxone for Streptococcus pneumonia	10 Participants	0 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; hospitalization/prolongation of hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Serious Adverse Events	0 Participants	2 Participants

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who had any medical conditions at the time of index hospitalization were reported in this outcome measure. Medical conditions that were considered included Human Immunodeficiency Virus (HIV) infection, alcohol abuse, cancer/malignancy, cerebrovascular disease, chronic dialysis within the past 30 days, chronic obstructive pulmonary disease, chronic renal disease, congestive heart failure, decompensated cirrhosis, diabetes mellitus, immunosuppressive disease, influenza, injection drug use, end stage liver disease, peripheral vascular disease, respiratory disease or any other relevant condition(s) or disease(s) that required chronic drug treatment. Index hospitalization was first hospitalization on or before May 31, 2019 where Zinforo was administered for the treatment of CAP or cSSTI.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Medical Conditions Presented at Index Hospitalization	147 Participants	99 Participants

PRIMARY outcome

Timeframe: 3 months prior to index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who had hospitalization for any reason, 3 months before the index hospitalization were reported in this outcome measure. Index hospitalization was first hospitalization on or before May 31, 2019 where Zinforo was administered for the treatment of CAP or cSSTI.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Hospitalization for Any Reason in the 3 Months Before the Index Hospitalization	34 Participants	44 Participants

PRIMARY outcome

Timeframe: 3 months prior to index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who had undergone surgical treatments, 3 months before to the index hospitalization were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Invasive Major Surgical Treatment in the 3 Months Before the Index Hospitalization	5 Participants	24 Participants

PRIMARY outcome

Timeframe: 3 months prior to index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Number of participants according to therapies received in the 3 months prior to index hospitalization were reported in this outcome measure. One participant could receive more than one therapy.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Antimicrobial (e.g. antibiotics, antivirals)	47 Participants	56 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Immunosuppressors/ immunomodulators	21 Participants	19 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Anticoagulants	38 Participants	45 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Non-steroid anti-inflammatory agents (NSAIs)	13 Participants	25 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Home infusion therapy	3 Participants	2 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization Home wound care provided by a medical professional	6 Participants	5 Participants
Number of Participants According to Therapies Received in the 3 Months Before the Index Hospitalization None	103 Participants	39 Participants

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Participants were categorized according to radiographic findings in the tests conducted for diagnosis of CAP infection in this outcome measure. One participant could have more than one radiographic finding.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Radiographic Findings in Tests for CAP Pleural effusion	48 Participants	—
Number of Participants With Radiographic Findings in Tests for CAP Other findings	30 Participants	—
Number of Participants With Radiographic Findings in Tests for CAP Infiltrate	130 Participants	—
Number of Participants With Radiographic Findings in Tests for CAP Consolidation	68 Participants	—
Number of Participants With Radiographic Findings in Tests for CAP None of the above	3 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Participants were categorized according to triggering signs and symptoms at CAP diagnosis and recorded at index hospital admission were reported in this outcome measure. The observed signs and symptoms were dyspnea, tachypnea, or hypoxemia (oxygen [O2] saturation < 90% on room air or partial pressure of oxygen (pO2) < 60 mmHg), Fever (>38 degree Celsius[C]oral; > 38.5 degree C rectally or tympanically) or hypothermia (< 35 degree C), White Blood Cell (WBC) count > 10,000 cells/cubic millimeter(mm³) or < 4,500 cells/mm³. One participant could have more than one signs or symptoms.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization New or increased cough	129 Participants	—
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Purulent sputum or change in sputum character	80 Participants	—
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Auscultatory findings consistent with pneumonia	138 Participants	—
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Dyspnea, tachypnea, or hypoxemia (O2 saturation < 90% on room air or pO2 < 60 mmHg)	148 Participants	—
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Fever (>38 degree C oral; > 38.5 degree C rectally or tympanically) or hypothermia (< 35 degree C)	127 Participants	—
CAP: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization WBC count > 10,000 cells/mm³ or < 4,500 cells/mm³	122 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

Number of participants diagnosed with severe CAP were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Severe CAP	128 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission(from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

In this outcome measure participants were categorized according to type of assessment used to assess CAP severity. Pneumonia severity index (PSI)/PORT score was used to calculate the probability of morbidity and mortality among participants with CAP. The score was used to predict the need for hospitalization in people with pneumonia. CURB- 65 was used to measure the confusion, blood urea, respiratory rate, blood pressure for the participants aged greater than or equal to 65 years. Multiple criteria to assess the severity of CAP exist. In this study severity was first globally assessed asking if a (any) criterion for severity of CAP would apply. In subsequent questions the details on the exact methods of the severity assessment were then asked. This included the information about PORT score / PSI, CURB-65 and recurrency of CAP.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Type of Prognostic Scoring System Used to Assess CAP Severity PORT Score / Pneumonia Severity Index	18 Participants	—
Number of Participants According to Type of Prognostic Scoring System Used to Assess CAP Severity CURB-65	41 Participants	—
Number of Participants According to Type of Prognostic Scoring System Used to Assess CAP Severity Other	15 Participants	—
Number of Participants According to Type of Prognostic Scoring System Used to Assess CAP Severity None	71 Participants	—
Number of Participants According to Type of Prognostic Scoring System Used to Assess CAP Severity Unknown	40 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The time taken (in days) taken to diagnose CAP in the participants prior to index hospitalization were reported in this outcome measure and this data was recorded at index hospitalization admission.

Outcome measures

Measure	Participants With CAP n=99 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time of CAP Diagnosis at Index Hospitalization	1 Days Interval 0.0 to 20.0	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants with recurrent CAP infections were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Recurrent CAP Infections at Index Hospitalization	10 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants were classified according to the various pathogens identified during CAP diagnosis in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Streptococcus pneumonia	44 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Escherichia coli	2 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Hemophilus influenza	3 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization H. Parainfluenza	1 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Legionella spp.	2 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Staphylococcus aureus	4 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Methicillin resistance Staphylococcus aureus	14 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Methicillin susceptible Staphylococcus. aureus	15 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Klebsiella pneumonia	3 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Other enterobacteria	2 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Pseudomonas aeruginosa	1 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Other microorganism	26 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization Unknown	15 Participants	—
Number of Participants According to Microbiological CAP Diagnosis at Index Hospitalization None of the above	72 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Analysis population included all eligible participants whose data were retrieved from hospital medical records and assessed. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants were classified according to the type of investigations performed for the microbiological CAP diagnosis and were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Sputum examination	33 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Blood culture	39 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Bronchoalveolar lavage or bronchial brush examination	10 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Pleural fluid sample examination	4 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Legionella antigen test in urine	5 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Pneumococcal antigen test in urine	30 Participants	—
Number of Participants According to Type of Investigation Performed for Positive Microbiological CAP Diagnosis at Index Hospitalization Other	17 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

In this outcome measure number of participants who had H1N1 Influenza virus determined using PCR were reported.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants With Polymerase Chain Reaction (PCR) Determination of H1N1 Influenza Virus at Index Hospitalization	71 Participants	—

PRIMARY outcome

Timeframe: 12 months prior to index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants according to the status of influenza vaccination were reported in this outcome measure, as vaccinated: Yes, No and Unknown.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants According to Influenza Vaccination Status During 12 Months Prior to Index Hospitalization Yes	32 Participants	—
CAP: Number of Participants According to Influenza Vaccination Status During 12 Months Prior to Index Hospitalization No	64 Participants	—
CAP: Number of Participants According to Influenza Vaccination Status During 12 Months Prior to Index Hospitalization Unknown	89 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants according to the status of pneumococcal vaccination were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants According to Pneumococcal Vaccination Status at Index Hospitalization Yes	18 Participants	—
CAP: Number of Participants According to Pneumococcal Vaccination Status at Index Hospitalization No	76 Participants	—
CAP: Number of Participants According to Pneumococcal Vaccination Status at Index Hospitalization Unknown	91 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in CAP participants.

The number of participants were classified according to the biomarkers used for monitoring the state of CAP in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
CAP: Number of Participants According to the Biomarkers Used for Monitoring Clinical Evolution at Index Hospitalization C-reactive protein (CRP)	182 Participants	—
CAP: Number of Participants According to the Biomarkers Used for Monitoring Clinical Evolution at Index Hospitalization Procalcitonin	73 Participants	—
CAP: Number of Participants According to the Biomarkers Used for Monitoring Clinical Evolution at Index Hospitalization Other biomarker	8 Participants	—
CAP: Number of Participants According to the Biomarkers Used for Monitoring Clinical Evolution at Index Hospitalization None of the above	2 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants classified according to the types of lesions involved in the cSSTI infection were reported in this outcome measure. One participant could have more than one type of lesion.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Abscess	45 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Cellulitis/fasciitis	82 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Post-traumatic wound	9 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Post-surgical wound	26 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Decubitus ulcer	5 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Diabetic leg ulcer	5 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Peripheral vascular disease ulcer	3 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Bite	1 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization Unknown	1 Participants	—
cSSTI: Number of Participants According to Type of Lesions Involved at Index Hospitalization None of the above	2 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants were classified according to the body area involved in cSSTI are reported in this outcome measure. One participant could have more than one type of body area involvement.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Head	13 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Hand	3 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Upper extremities	14 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Lower extremities	74 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Thorax	19 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Abdomen	14 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Genitalia	9 Participants	—
cSSTI: Number of Participants According to Type of Body Area Involved at Index Hospitalization Unknown	1 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants were classified according to the extent of skin that was affected with the infection in this outcome measure.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Area of Extension of Skin Infection at Index Hospitalization Less than (<) 5 centimeter square (cm^2)	12 Participants	—
cSSTI: Number of Participants According to Area of Extension of Skin Infection at Index Hospitalization 5-10 cm^2	31 Participants	—
cSSTI: Number of Participants According to Area of Extension of Skin Infection at Index Hospitalization 10-50 cm^2	34 Participants	—
cSSTI: Number of Participants According to Area of Extension of Skin Infection at Index Hospitalization Greater than (>) 50 cm^2	8 Participants	—
cSSTI: Number of Participants According to Area of Extension of Skin Infection at Index Hospitalization Unknown	47 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants were classified according to the level of infections in this outcome measure.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Level of Infections at Index Hospitalization Superficial	51 Participants	—
cSSTI: Number of Participants According to Level of Infections at Index Hospitalization Deep incisional	51 Participants	—
cSSTI: Number of Participants According to Level of Infections at Index Hospitalization Organ or space infection	20 Participants	—
cSSTI: Number of Participants According to Level of Infections at Index Hospitalization Unknown	10 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants were classified according to the anatomical structures involved in the infections in this outcome measure.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Epithelium	61 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Epidermis	92 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Dermis	88 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Subcutaneous fat	61 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Fascia	23 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Muscle	25 Participants	—
cSSTI: Number of Participants According to Type of Anatomical Structures Affected at Index Hospitalization Unknown	23 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The time taken (in days) taken to diagnose cSSTI in the participants prior to index hospitalization were reported in this outcome measure and this data was recorded at index hospitalization admission.

Outcome measures

Measure	Participants With CAP n=51 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time of cSSTI Diagnosis at Index Hospitalization	5 Days Interval 0.0 to 100.0	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants that had recurrent cSSTI infections were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants With Recurrent Infection at Index Hospitalization	33 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants with triggering signs and symptoms during the cSSTI diagnosis were reported in this outcome measure. One participant could have more than one triggering signs and symptoms.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Purulent or seropurulent drainage/discharge	65 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Bullae	5 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Erythema	106 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Fluctuance	30 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Heat/localized warmth	90 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Pain/tenderness to palpitation	100 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Swelling/induration	78 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Skin necrosis	9 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Anesthesia	1 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Crackling	3 Participants	—
cSSTI: Number of Participants With Triggering Signs and Symptoms at Index Hospitalization Induration beyond the erythematous area	17 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants were classified according to the systemic signs observed Including temperature greater than (>) 30 degree Celsius, White blood cell count >10,000 cells per millimeter cube(/mm3) or <4,500/mm3 or immature neutrophils >10%, septic shock, organ dysfunction and none of the above mentioned were reported. One participant could have more than one systemic sign.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Systemic Signs of cSSTI at Index Hospitalization Temperature > 38 degree Celsius	77 Participants	—
Number of Participants According to Systemic Signs of cSSTI at Index Hospitalization White blood cell count	108 Participants	—
Number of Participants According to Systemic Signs of cSSTI at Index Hospitalization Septic shock	4 Participants	—
Number of Participants According to Systemic Signs of cSSTI at Index Hospitalization Organ dysfunction	13 Participants	—
Number of Participants According to Systemic Signs of cSSTI at Index Hospitalization None of the above	1 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

The number of participants classified according to the diagnostic tests conducted to diagnose cSSTI were reported in this outcome measure. One participant could have more than one type of diagnostic test.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Blood cultures	85 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Superficial swab and culture	40 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Needle aspiration	14 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Skin biopsy	7 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Surgical sample	22 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization X-ray	31 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Ultrasound	58 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Computed Tomography (CT)/ Magnetic Resonance Imaging (MRI)	35 Participants	—
cSSTI: Number of Participants According to Type of Diagnostic Tests Conducted at Index Hospitalization Unknown/not performed	6 Participants	—

PRIMARY outcome

Timeframe: At index hospitalization admission (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. This outcome measure was planned to be analyzed only in cSSTI participants.

Pathogens identified by blood or skin/soft tissue/bone/wound cultures were recorded for participants with cSSTI.

Outcome measures

Measure	Participants With CAP n=132 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Unknown	24 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Methicillin resistance Staphylococcus aureus	24 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Methicillin susceptible S. aureus (MSSA)	23 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Staphylococcus coagulase negative	8 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Streptococcus pneumonia	1 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Streptococcus pyogenes	4 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Streptococcus agalactiae	1 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Enterococcus faecalis	2 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Gram-negative bacilli	12 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Non-fermenting enterobacteria	1 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Other strict anaerobic bacteria	1 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Other microorganism	8 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization Mixed flora	1 Participants	—
cSSTI: Number of Participants According to Microbiologic Diagnosis at Index Hospitalization None of the above	40 Participants	—

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to types of antibiotics that they received prior to Zinforo and reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Aminoglycoside	5 Participants	6 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Betalactam	17 Participants	20 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Carbapenem	12 Participants	4 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Ceftriaxone	45 Participants	10 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Cephalosporins	19 Participants	16 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Glycopeptide	4 Participants	18 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Macrolide	13 Participants	23 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Betalactam/Combination	36 Participants	6 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Quinolone	50 Participants	21 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Sulfonamide	37 Participants	10 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Clindamycin	1 Participants	4 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Other antibiotic agent	15 Participants	8 Participants
Number of Participants According to Class of Antibiotics Received Prior to Zinforo Treatment During Index Hospitalization Unknown	17 Participants	31 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to the lines of therapy in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization First	134 Participants	87 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Second	85 Participants	58 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Third	40 Participants	24 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Fourth	20 Participants	13 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Fifth	5 Participants	5 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Sixth	2 Participants	3 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Seventh	1 Participants	3 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Eighth	1 Participants	3 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Nineth	0 Participants	1 Participants
Number of Participants According to Lines of Pre-Zinforo Therapies During Index Hospitalization Tenth	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants'' analyzed signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to various routes of administration for pre-Zinforo treatment and were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Routes of Administration for Pre-Zinforo Treatment During Index Hospitalization Oral	44 Participants	31 Participants
Number of Participants According to Routes of Administration for Pre-Zinforo Treatment During Index Hospitalization Intra-venous	111 Participants	73 Participants
Number of Participants According to Routes of Administration for Pre-Zinforo Treatment During Index Hospitalization Intra-muscular	7 Participants	0 Participants
Number of Participants According to Routes of Administration for Pre-Zinforo Treatment During Index Hospitalization Subcutaneous	0 Participants	1 Participants
Number of Participants According to Routes of Administration for Pre-Zinforo Treatment During Index Hospitalization Unknown	4 Participants	3 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants'' analyzed signifies number of participants evaluable for this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration of Pre-Zinforo Treatment During Index Hospitalization	6 Days Interval 0.0 to 45.0	8 Days Interval 1.0 to 40.0

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time From Symptom Onset to First Dose of Pre-Zinforo Treatment	3 Days Interval 0.0 to 20.0	2 Days Interval 0.0 to 30.0

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to types of Pre-Zinforo treatment and were reported in this outcome measure. One participant could have more than one type of pre-Zinforo treatment.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Types of Pre-Zinforo Treatment During Index Hospitalization Empiric	129 Participants	74 Participants
Number of Participants According to Types of Pre-Zinforo Treatment During Index Hospitalization Definitive/Specific	13 Participants	19 Participants
Number of Participants According to Types of Pre-Zinforo Treatment During Index Hospitalization Unknown	6 Participants	10 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Doses Administered for Pre-Zinforo Treatment During Index Hopsitalization	2.02 Doses Standard Deviation 0.93	2.18 Doses Standard Deviation 1.54

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants'' analyzed signifies number of participants evaluable for this outcome measure.

The number of participants who had pre-Zinforo treatment modification were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Pre-Zinforo Treatment Modification During Index Hospitalization	91 Participants	60 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants classified according to the reasons for pre-Zinforo treatment modification were reported in this outcome measure. One participant could have more than one reason for treatment modification. Index hospitalization was first hospitalization on or before May 31, 2019 where Zinforo was administered for the treatment of CAP or cSSTI. One participant could have more than one reason for treatment modification.

Outcome measures

Measure	Participants With CAP n=91 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=60 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Reasons for Pre-Zinforo Treatment Modification Other	14 Participants	16 Participants
Number of Participants According to Reasons for Pre-Zinforo Treatment Modification Adverse event	5 Participants	3 Participants
Number of Participants According to Reasons for Pre-Zinforo Treatment Modification Insufficient response	58 Participants	42 Participants
Number of Participants According to Reasons for Pre-Zinforo Treatment Modification Possible interaction with other drug	1 Participants	1 Participants
Number of Participants According to Reasons for Pre-Zinforo Treatment Modification Streamlining	29 Participants	9 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was of 102 days for CAP; 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

Treatment response was defined according to the following criteria: CAP participants who demonstrated clinical stability (defined according to the Infectious Diseases Society of America [IDSA] guidelines as temperature of ≤37.8 C°, heart rate of ≤100 beats/min, respiratory rate of ≤24 breaths/min, systolic blood pressure of ≥90mmHg, oxygen saturation of ≥90%, and confusion/disorientation recorded as absent) and clinical improvement{defined as improvement of at least 1 of 4 symptoms present at baseline (i.e., cough, dyspnea, pleuritic chest pain, sputum production) with worsening of none}. cSSTI participants: ≥20% reduction from baseline infection area and cessation of spread measured by total infection area. The number of participants were classified according to treatment response to pre-Zinforo treatment and were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Based on Treatment Response to Pre-Zinforo Treatment During Index Hospitalization Response	12 Participants	17 Participants
Number of Participants Based on Treatment Response to Pre-Zinforo Treatment During Index Hospitalization No response	89 Participants	14 Participants
Number of Participants Based on Treatment Response to Pre-Zinforo Treatment During Index Hospitalization Unknown	33 Participants	62 Participants

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The time (days) taken for modification from initial dose of pre-Zinforo treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=91 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=60 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time to Treatment Modification From Initial Dose of Pre-Zinforo Treatment	2 Days Interval 0.0 to 13.0	3 Days Interval 0.0 to 20.0

PRIMARY outcome

Timeframe: Before Zinforo treatment initiation during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants with insufficient response to pre-Zinforo treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=134 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=87 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Insufficient Response to Pre-Zinforo Treatment During Index Hospitalization	58 Participants	42 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The duration of Zinforo treatment for CAP and cSSTI infections were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration of Zinforo Treatment During Index Hospitalization	7 Days Interval 2.0 to 35.0	8 Days Interval 2.0 to 60.0

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The time taken from admission to the administration of first dose of Zinforo was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time From Admission to First Dose of Zinforo During Index Hospitalization	1 Days Interval 0.0 to 36.0	1 Days Interval 0.0 to 60.0

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The time taken for the symptom onset to the administration of first dose of Zinforo was reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Time From Symptom Onset to First Dose of Zinforo During Index Hospitalization	6 Days Interval 0.0 to 38.0	7 Days Interval 0.0 to 64.0

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants classified according to the types of treatment for Zinforo were reported in this outcome measure. Types included empiric, definitive/specific and unknown. Empiric was defined as therapy administered to participants prior to the results of blood culture and susceptibility tests. Definitive was defined as therapy administered after the test results were received.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Types of Treatment for Zinforo Empiric	138 Participants	84 Participants
Number of Participants According to Types of Treatment for Zinforo Definitive/Specific	41 Participants	43 Participants
Number of Participants According to Types of Treatment for Zinforo Unknown	6 Participants	5 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Daily Dose of Zinforo	1183.24 Milligrams Standard Deviation 412.69	1239.39 Milligrams Standard Deviation 402.43

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Infusions Administered Daily for Zinforo	2.28 Infusions Standard Deviation 0.47	2.27 Infusions Standard Deviation 0.46

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to the locations where Zinforo was administered were reported in this outcome measure. One participant could have more than one location of Zinforo administration.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Locations of Zinforo Administration Intensive Care Unit (ICU)	66 Participants	11 Participants
Number of Participants According to Locations of Zinforo Administration General ward	115 Participants	114 Participants
Number of Participants According to Locations of Zinforo Administration At home	1 Participants	14 Participants
Number of Participants According to Locations of Zinforo Administration Medical clinic	30 Participants	14 Participants
Number of Participants According to Locations of Zinforo Administration Out-patient setting	0 Participants	2 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to Zinforo administration as monotherapy or combination therapy were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Administered Zinforo as Monotherapy or Combination Therapy Monotherapy	56 Participants	78 Participants
Number of Participants Administered Zinforo as Monotherapy or Combination Therapy Combination therapy	129 Participants	54 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Number of participants who received concomitant therapies along with Zinforo were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Receiving Concomitant Therapies Along With Zinforo	131 Participants	92 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to types of antibiotics received for index infection (CAP and cSSTI) after the Zinforo treatment were reported in this outcome measure. One participant could receive more than one type of antibiotic.

Outcome measures

Measure	Participants With CAP n=99 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=75 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Aminoglycoside	9 Participants	3 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Betalactam	13 Participants	4 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Carbapenem	8 Participants	5 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Ceftriaxone	18 Participants	15 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Glycopeptide	7 Participants	5 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Macrolide	12 Participants	2 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Betalactam/Combination	27 Participants	12 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Quinolone	45 Participants	28 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Sulfonamide	12 Participants	2 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Clindamycin	32 Participants	21 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Other antibiotic agent	12 Participants	20 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Linezolid	0 Participants	2 Participants
Number of Participants According to Type of Antibiotics Received for Index Infection After Zinforo Treatment Unknown	9 Participants	0 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to the lines of therapy for post-Zinforo treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=99 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=75 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment First	1 Participants	2 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Second	45 Participants	46 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Third	40 Participants	20 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Fourth	51 Participants	21 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Fifth	26 Participants	11 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Sixth	25 Participants	5 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Seventh	5 Participants	5 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Eighth	8 Participants	2 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Nineth	3 Participants	4 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Tenth	0 Participants	1 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Eleventh	0 Participants	1 Participants
Number of Participants According to Lines of Therapy for Post-Zinforo Treatment Twelfth	0 Participants	1 Participants

PRIMARY outcome

Timeframe: CAP (up to maximum of 102 days), cSSTI (up to maximum of 162 days)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to routes of administration for post-Zinforo treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Route of Administration for Post-Zinforo Treatment Oral	92 Participants	81 Participants
Number of Participants According to Route of Administration for Post-Zinforo Treatment Intra-venous	112 Participants	38 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The duration in days from Zinforo treatment discontinuation to initiation of new treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration From Zinforo Discontinuation to Initiation of New Treatment	1 Days Interval 0.0 to 56.0	1 Days Interval 0.0 to 36.0

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Doses Administered for Post Zinforo Treatment	11.05 Doses Standard Deviation 14.82	16.38 Doses Standard Deviation 21.81

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to the reasons for switching to post-Zinforo treatment were reported in this outcome measure. One participant could have more than one reason for switch.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Reasons for Switching to Post-Zinforo Treatment Lack of efficacy of previous treatment	39 Participants	9 Participants
Number of Participants According to Reasons for Switching to Post-Zinforo Treatment Side effect of previous treatment	1 Participants	9 Participants
Number of Participants According to Reasons for Switching to Post-Zinforo Treatment Results of susceptibility test/pathogen identification	26 Participants	14 Participants
Number of Participants According to Reasons for Switching to Post-Zinforo Treatment Other	124 Participants	81 Participants
Number of Participants According to Reasons for Switching to Post-Zinforo Treatment Unknown	14 Participants	6 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical response in CAP:participants demonstrating clinical stability(i.e.,according to IDSA guidelines:temperature of<=37.8 degree Celsius,heart rate of <=100 beats per minute,respiratory rate of <=24 breaths per minute,systolic blood pressure of >=90 mmHg,oxygen saturation of >=90%,confusion/disorientation recorded as absent),clinical improvement(i.e.,improvement of at least 1 of 4 symptoms present at Baseline(i.e.,cough,dyspnea,pleuritic chest pain,sputum production)with worsening of none).Clinical response in cSSTI participants:>=20% reduction from baseline infection area,cessation of spread measured by total infection area.Clinical failure for both CAP and cSSTI:any of the following:treatment modification due to AE;drug-drug interaction;insufficient response(followed by switch);death due to index infection;death due to other cause;relapse or recurrence. Number of participants classified according to treatment responses to post-Zinforo treatment reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Based on Treatment Response to Post-Zinforo Treatment Clinical response	155 Participants	95 Participants
Number of Participants Based on Treatment Response to Post-Zinforo Treatment Clinical failure	26 Participants	4 Participants
Number of Participants Based on Treatment Response to Post-Zinforo Treatment Unknown	23 Participants	20 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to the locations in which post-Zinforo treatment was administered. One participant could have more than one location of administration.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration At home	64 Participants	70 Participants
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration ICU	70 Participants	1 Participants
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration General ward	86 Participants	42 Participants
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration Out-patient setting	9 Participants	16 Participants
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration Medical clinic	6 Participants	5 Participants
Number of Participant According to Type of Location for Post-Zinforo Treatment Administration Other	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Clinical response in CAP was defined as participants demonstrating clinical stability (i.e., according to the IDSA guidelines a temperature of <=37.8 degree Celsius, heart rate of <=100 beats per minute, respiratory rate of <=24 breaths per minute, systolic blood pressure of >=90 mmHg, oxygen saturation of >=90%, and confusion/disorientation recorded as absent) and clinical improvement (i.e., improvement of at least 1 of 4 symptoms present at Baseline (i.e., cough, dyspnea, pleuritic chest pain, sputum production) with worsening of none). Clinical response in cSSTI participants was defined as >=20% reduction from baseline infection area and cessation of spread measured by total infection area.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Achieved Clinical Response to Post-Zinforo Treatment	139 Participants	89 Participants

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants'' analyzed signifies number of participants evaluable for this outcome measure.

Clinical failure for both CAP and cSSTI was defined as any of the following: treatment modification due to AE; drug-drug interaction; insufficient response (followed by switch); death due to index infection; death due to other cause; relapse or recurrence. The number of participants were classified according to the reasons for clinical failure post-Zinforo treatment were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=26 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=4 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Reasons for Clinical Failure to Post-Zinforo Treatment Treatment modification due to adverse event	2 Participants	0 Participants
Number of Participants According to Reasons for Clinical Failure to Post-Zinforo Treatment Insufficient response	14 Participants	1 Participants
Number of Participants According to Reasons for Clinical Failure to Post-Zinforo Treatment Relapse/reoccurrence	1 Participants	0 Participants
Number of Participants According to Reasons for Clinical Failure to Post-Zinforo Treatment Death due to infection	6 Participants	0 Participants
Number of Participants According to Reasons for Clinical Failure to Post-Zinforo Treatment Death due to other	3 Participants	3 Participants

PRIMARY outcome

Timeframe: Day 1 of admission of index hospitalization to discharge from hospital (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Index hospitalization was first hospitalization on or before May 31, 2019 where Zinforo was administered for the treatment of CAP or cSSTI.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration of Index Hospitalization	12 Days Interval 3.0 to 102.0	11 Days Interval 3.0 to 162.0

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration in Intensive Care Unit	0 Days Interval 0.0 to 46.0	0 Days Interval 0.0 to 41.0

PRIMARY outcome

Timeframe: Post initiation of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who received renal replacement therapy after initiating treatment with Zinforo were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Received Renal Replacement Therapy Post Initiating Treatment With Zinforo	5 Participants	2 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants were classified according to treatments received during index hospitalization were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Treatments Received During Index Hospitalization Surgery related to the infection	5 Participants	37 Participants
Number of Participants According to Treatments Received During Index Hospitalization Surgery unrelated to the infection	1 Participants	0 Participants
Number of Participants According to Treatments Received During Index Hospitalization Blood pressure support	44 Participants	12 Participants
Number of Participants According to Treatments Received During Index Hospitalization Blood pressure support: Fluid resuscitation	32 Participants	7 Participants
Number of Participants According to Treatments Received During Index Hospitalization Blood pressure support: Vasopressors	44 Participants	10 Participants
Number of Participants According to Treatments Received During Index Hospitalization Blood pressure support: Invasive procedures	2 Participants	0 Participants
Number of Participants According to Treatments Received During Index Hospitalization None of the above	139 Participants	90 Participants

PRIMARY outcome

Timeframe: Within 30 days post discharge from index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who received home-based care through a healthcare agency were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Received Home-Based Care Through a Healthcare Agency	16 Participants	35 Participants

PRIMARY outcome

Timeframe: Within 30 days post discharge from index hospitalization (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who had re-hospitalizations were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Re-hospitalizations	20 Participants	13 Participants

PRIMARY outcome

Timeframe: Day 1 of re-hospitalization till discharge (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants analyzed'' signifies number of participants evaluable for this outcome measure.

In this outcome measure, data is recorded for duration (in days) of re-hospitalization (if any) that happened within 30 days post discharge from index hospitalization.

Outcome measures

Measure	Participants With CAP n=20 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=13 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Duration of Re-hospitalizations	10.5 Days Interval 1.0 to 39.0	9 Days Interval 2.0 to 30.0

PRIMARY outcome

Timeframe: Day 1 of re-hospitalization till discharge (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database. Here, ''Overall number of participants'' analyzed signifies number of participants evaluable for this outcome measure.

The number of participants were classified according to reasons for re-hospitalizations were reported in this outcome measure. Re-hospitalization (if any) that happened within 30 days post discharge from index hospitalization.

Outcome measures

Measure	Participants With CAP n=20 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=13 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants According to Reasons for Re-hozpitalization For index infection	7 Participants	3 Participants
Number of Participants According to Reasons for Re-hozpitalization For other reason	13 Participants	10 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who developed sepsis during index hospitalization were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Development of Sepsis During Index Hospitalization	38 Participants	29 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The qSOFA (also known as quickSOFA) was a bedside prompt that identified participants with suspected infection who are at greater risk for a poor outcome outside the intensive care unit (ICU). It used three criteria, assigning one point for low blood pressure Systolic blood pressure less than or equal to 100 millimeters of mercury (SBP<=100 mmHg), high respiratory rate greater than or equal to (>=) 22 breaths per min, or altered mentation (Glasgow coma scale<15).

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants With Quick Sepsis-Related Organ Failure Assessment (qSOFA) Conducted	74 Participants	40 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who required isolation were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Requiring Isolation	20 Participants	10 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Received Mechanical Ventilation, Oxygen Therapy and Parenteral Nutrition Mechanical Ventilation	56 Participants	11 Participants
Number of Participants Who Received Mechanical Ventilation, Oxygen Therapy and Parenteral Nutrition Oxygen Therapy	37 Participants	6 Participants
Number of Participants Who Received Mechanical Ventilation, Oxygen Therapy and Parenteral Nutrition Parenteral Nutrition	17 Participants	5 Participants

PRIMARY outcome

Timeframe: During index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The number of participants who suffered from acute renal failure and necessitated renal replacement were reported in this outcome measure.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Number of Participants Who Suffered Acute Renal Failure Necessitating Renal Replacement	11 Participants	4 Participants

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Total Number of Doses of Zinforo Administered	18.96 Doses Standard Deviation 11.05	23.29 Doses Standard Deviation 18.2

PRIMARY outcome

Timeframe: Day 1 of Zinforo treatment till end of Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Total Number of Doses of Other Antibiotics Administered in Combination With Zinforo	8.48 Doses Standard Deviation 9.81	8.48 Doses Standard Deviation 9.81

PRIMARY outcome

Timeframe: Post Zinforo treatment, during index hospitalization, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Total Dose of Other Antibiotics Administered Post Zinforo Treatment	11.05 Milligrams Standard Deviation 14.82	11.05 Milligrams Standard Deviation 14.82

PRIMARY outcome

Timeframe: Day 1 of index hospitalization till discharge, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study)

Population: Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.

The cost of hospitalization of standard level hospitals was calculated as total hospital cost= total number of bed days * per diem rate standard hospital general ward and the cost of hospitalization of advanced level hospitals was calculated as total number of bed days * per diem rate advanced hospital.

Outcome measures

Measure	Participants With CAP n=185 Participants Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 Participants Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Cost of Hospitalization Standard hospital cost	9204.62 US dollars Standard Deviation 12895.23	5196.2 US dollars Standard Deviation 9070.35
Cost of Hospitalization Advanced level cost	25408.01 US dollars Standard Deviation 31704.58	20257.18 US dollars Standard Deviation 36809.71

Adverse Events

Participants With CAP

Serious events: 0 serious events

Other events: 0 other events

Deaths: 31 deaths

Participants With cSSTI

Serious events: 2 serious events

Other events: 0 other events

Deaths: 15 deaths

Serious adverse events

Measure	Participants With CAP n=185 participants at risk Participants hospitalized for CAP and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 7 days.	Participants With cSSTI n=132 participants at risk Participants hospitalized for cSSTI and treated with 4 or more IV doses of Zinforo on or before 31-May-2019 were observed during this retrospective chart review study. The recommended dose of Zinforo was 600 mg administered every 12 hours by intravenous infusion over 60 minutes for 5 to 14 days.
Blood and lymphatic system disorders Agranulocytosis	0.00% 0/185 • For adverse events: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI; For death: Day 1 of index hospitalization up to 30 days of discharge, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study) The adverse events attributed only to Zinforo treatment during index hospitalization as observed from medical records of participants were reported. There was no specific medical dictionary utilized to record adverse events.	0.76% 1/132 • For adverse events: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI; For death: Day 1 of index hospitalization up to 30 days of discharge, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study) The adverse events attributed only to Zinforo treatment during index hospitalization as observed from medical records of participants were reported. There was no specific medical dictionary utilized to record adverse events.
General disorders Drug hypersensitivity	0.00% 0/185 • For adverse events: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI; For death: Day 1 of index hospitalization up to 30 days of discharge, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study) The adverse events attributed only to Zinforo treatment during index hospitalization as observed from medical records of participants were reported. There was no specific medical dictionary utilized to record adverse events.	0.76% 1/132 • For adverse events: Day 1 of Zinforo treatment till end of Zinforo treatment: up to maximum of 35 days for CAP; up to maximum of 60 days for cSSTI; For death: Day 1 of index hospitalization up to 30 days of discharge, index hospitalization was maximum of 102 days for CAP; maximum of 162 days for cSSTI (from the retrospective data evaluated in approximately 14 months of the study) The adverse events attributed only to Zinforo treatment during index hospitalization as observed from medical records of participants were reported. There was no specific medical dictionary utilized to record adverse events.

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Results disclosure agreements

• Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
• Publication restrictions are in place

Restriction type: OTHER